Vaxart (VXRT) announced the initiation of a Phase 1, open label, dose ranging clinical trial evaluating its second-generation oral norovirus ...

Vaxart (NASDAQ:VXRT – Get Free Report) is expected to release its earnings data before the market opens on Thursday, March ...

Conference call to begin at 4:30 p.m. ETSOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today ...

- Topline data expected as early as mid-2025 - SOUTH SAN FRANCISCO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the initiation of a Phase 1, open label ...

Oral Vaccine Focused Penny Stock Vaxart Is 'Uniquely Positioned', Analyst Sees Almost 83% Upside Oppenheimer initiates Vaxart coverage with an Outperform rating and $4 price target, citing a ...

Federal funding for a Bay Area biotech company's potential half-billion-dollar oral Covid-19 vaccine project has been paused ...

Vaxart Inc (NASDAQ:VXRT) shares are trading higher in Monday’s after-hours session after the company provided business and cash runway updates. What Happened: Vaxart, a clinical-stage ...

June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an underwritten offering of 50,000,000 shares of its common stock at an offering price of $0.80 per ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The awards consisted of stock options to purchase an aggregate of 61,000 shares of Vaxart’s common stock, whi Vaxart ( NASDAQ:VXRT ) Third Quarter 2024 Results Key Financial Results Revenue: US$4.93m ...